<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 position-relative fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook pt-3 mb-0">MM1: Ixazomib (NINLARO) + Rd extended PFS in pre-treated patients with RRMM who received 2 to 3 prior therapies<sup>1</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page21_middle_box page28_middle_box mt-3 mb-4" style="position:relative;">
                <div class="page21_middle_left page28_middle_left">
                    <h4 class="txt_orange GothamBook mt-5 pt-4 mb-3 positionCtrl">TOURMALINE-MM1 CLINICAL TRIAL EFFICACY IN PRE-TREATED PATIENTS<sup>1</sup></h4>
                    <div>
                        <h5 class="page21_blue GothamBold" style="margin-top: 100px;">In patients with 2 to 3 prior therapies, Ixazomib (NINLARO) + Rd <br>extended PFS by 42% vs placebo (NR vs 12.9 months, HR 0.58)<sup>1,*</sup></h5>
                        <img class="img-fluid graph21Ctrl" src="img/page28_chart.png" alt="">
                        <div class="page21_table pt-4 fs-11">
                            <div class="page21_table_header">
                                <div class="p21_tcol_1">
                                    <p class="txt_blue GothamMedium mb-0 py-1  fs-11">Time <br> (months)</p>
                                </div>
                                <div class="p21_tcol_2">
                                    <p class="txt_blue GothamBook mb-0 py-1  fs-11">0</p>
                                </div>
                                <div class="p21_tcol_3">
                                    <p class="txt_blue GothamBook mb-0 py-1  fs-11">6</p>
                                </div>
                                <div class="p21_tcol_4">
                                    <p class="txt_blue GothamBook mb-0 py-1  fs-11">12</p>
                                </div>
                                <div class="p21_tcol_5">
                                    <p class="txt_blue GothamBook mb-0 py-1  fs-11">18</p>
                                </div>
                                <div class="p21_tcol_6">
                                    <p class="txt_blue GothamBook mb-0 py-1  fs-11">24</p>
                                </div>
                            </div>
                            <p class="dark_secondary GothamMedium mb-0 py-2 text-start  fs-11">Patients at risk (n)</p>
                            <div class="page21_table_row">
                                <div class="p21_tcol_1">
                                    <p class="txt_orange GothamMedium mb-0 py-1 text-start  fs-11">Ixazomib (NINLARO) + Rd</p>
                                </div>
                                <div class="p21_tcol_2">
                                    <p class="txt_orange GothamBook mb-0 py-1  fs-11">148</p>
                                </div>
                                <div class="p21_tcol_3">
                                    <p class="txt_orange GothamBook mb-0 py-1  fs-11">112</p>
                                </div>
                                <div class="p21_tcol_4">
                                    <p class="txt_orange GothamBook mb-0 py-1  fs-11">59</p>
                                </div>
                                <div class="p21_tcol_5">
                                    <p class="txt_orange GothamBook mb-0 py-1  fs-11">15</p>
                                </div>
                                <div class="p21_tcol_6">
                                    <p class="txt_orange GothamBook mb-0 py-1  fs-11">0</p>
                                </div>
                            </div>
                            <div class="page21_table_row">
                                <div class="p21_tcol_1">
                                    <p class="dark_secondary GothamMedium mb-0 py-1 text-start  fs-11">Placebo + Rd</p>
                                </div>
                                <div class="p21_tcol_2">
                                    <p class="dark_secondary GothamBook mb-0 py-1  fs-11">149</p>
                                </div>
                                <div class="p21_tcol_3">
                                    <p class="dark_secondary GothamBook mb-0 py-1  fs-11">92</p>
                                </div>
                                <div class="p21_tcol_4">
                                    <p class="dark_secondary GothamBook mb-0 py-1  fs-11">43</p>
                                </div>
                                <div class="p21_tcol_5">
                                    <p class="dark_secondary GothamBook mb-0 py-1  fs-11">12</p>
                                </div>
                                <div class="p21_tcol_6">
                                    <p class="dark_secondary GothamBook mb-0 py-1  fs-11">0</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="page21_middle_right">
                <div class="page21_blue_box mb-5 mt-5">
                    <p class="mb-0 pe-4 fs-11">At <strong>23 months’</strong> median follow-up, median OS <br> was not reached in either group (HR=0.65, <br> 95% CI, 0.41–1.02)<sup>2</sup></p>
                </div>
                <div class="page21_blue_box">
                    <p class="mb-0 pe-4 fs-11"><strong>42%</strong> reduced risk of progression or death <br> with Ixazomib (NINLARO) + Rd vs placebo <br> + Rd (HR = 0.58; 95% CI, 0.40–0.84; <br> P=0.0033)</p>
                </div>
            </div>
    </div>
        <!--  -->
            <div class="page5_middle_box pt-1 mb-1">
                <div class="page5_btns_sm">
                    <a href="../page29/index.html" class="text-uppercase"><p class="mb-0 position-relative">REAL-WORLD EVIDENCE</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm w-75">
                <p class="GothamLight mb-2 pt-2">*At 14.8 months’ median follow-up.<sup>1</sup> <br>
                    CI = confidence interval; HR = hazard ratio; NR = not reached; OS = overall survival; PFS = progression-free survival; Rd = REVLIMID® (lenalidomide) + dexamethasone;
                    RRMM = relapsed/refractory multiple myeloma.</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page30/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>